Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 775-780, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witte, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witte, D. L.

Clinical Chemistry, Vol 41, 775-780, Copyright © 1995 by American Association for Clinical Chemistry

Measuring outcomes: why now?

DL Witte
Laboratory Control, Ltd., Ottumwa, IA 52501, USA.

Intense scrutiny of the American healthcare paradigm will alter the activities of patients, providers, and payors. Government reform and marketplace-driven managed care programs create uncertainty. Quality, access, and cost concerns also drive change. Quality is conformity to requirements, and specification of requirements creates policy debate. Variability in utilization creates an accountability chasm between payors and providers that cannot be bridged without understanding the uncertainties in "appropriateness" research. Quality and access appear secondary to cost. Cost discussions must differentiate cost and charge. Inappropriate charge benefit analyses may temporarily benefit a specific organization but are unlikely to create long-term societal benefit. Multiple transitions have begun, including a shift from disease care to healthcare, provider mentality to consumer mentality, and provider autonomy to collaboration and accountability. Laboratories will be expected to provide outcomes, not tests; income will be related to covered lives, not volume, and profit will shift from "piecework and efficiency profit" to "prevention profit." Only good "outcomes" measurement can reduce uncertainty. The laboratory contribution to value in care processes remains unclear. What information is added by each result? How can results help prevent the need for future services? These are our challenges.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
C. P. Price
Evidence-based Laboratory Medicine: Supporting Decision-Making
Clin. Chem., August 1, 2000; 46(8): 1041 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. L. Witte, S. A. VanNess, D. S. Angstadt, and B. J. Pennell
Errors, mistakes, blunders, outliers, or unacceptable results: how many?
Clin. Chem., August 1, 1997; 43(8): 1352 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. L. Witte
Mild liver enzyme abnormalities: eliminating hemochromatosis as cause
Clin. Chem., August 1, 1997; 43(8): 1535 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 Eval RevHome page
M. S. Salzer, C. T. Nixon, L. J. A. Schut, M. S. Karver, and L. Bickman
Validating Quality Indicators: Quality as Relationship Between Structure, Process, and Outcome
Eval Rev, June 1, 1997; 21(3): 292 - 309.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.